Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review by Xiaojing Liang, Guoqing Xu, Jisong Zhang, Li Xu, Liangliang Dong, Xiaoyue Wang, Weidong Han, Enguo Chen

Subjects: Get full text

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis by Xinyu Zhang, Bei Zhang, Danfei Li, Yunchao Yang, Sen Lin, Ruiqi Zhao, Yijia Li, Lisheng Peng

Subjects: “…immune checkpoint inhibitors…”
Get full text

Baseline (derived) neutrophil-lymphocyte ratio associated with survival in gastroesophageal junction or gastric cancer treated with ICIs by Chengyang Yu, Hao Jiang, Liezhi Wang, Zufu Jiang, Chong Jin

Subjects: “…immune checkpoint inhibitors…”
Get full text

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer by Nan Niu, Keyu Li, Junke Wang, Vanessa Funes, Birginia Espinoza, Pan Li, Jianxin Wang, Melissa Lyman, Mengni He, Brian Herbst, Michael Wichroski, Ruslan Novosiadly, Sami Shoucair, Yiping Mou, Lei Zheng

Subjects: Get full text

Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study by Malte Beckmann, Julian Schlüter, Michael Erdmann, Rafaela Kramer, Sarah Cunningham, Holger Hackstein, Robert Zimmermann, Lucie Heinzerling

Subjects: “…Immune checkpoint inhibitors…”
Get full text

The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies by Qingzhe Wang, Min Yu, Shuang Zhang

Subjects: Get full text

Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics by Shi-liang Chen, Yi-Ran Fei, Yi-Ran Fei, Xin-xian Cai, Xin-xian Cai, Cong Wang, Shi-yuan Tong, Zhe-zhong Zhang, Yan-xia Huang, Dan-dan Bian, Yi-bo He, Xiao-xiao Yang

Subjects: Get full text

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors by Yuhui Yang, Yuhui Yang, Yuhui Yang, Pingping Long, Pingping Long, Ying Tuo, Ying Tuo, Xiaoxiao Wang

Subjects: “…immune checkpoint inhibitors…”
Get full text

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities by Wen-yu Cai, Xin-xian Cai, Yi-ran Fei, Rui Ye, Ding-ming Song, Dan Hu, Wan-wan Zhang, Ming-fei Xia, Xiao-xiao Yang

Subjects: Get full text

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classifi... by Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang

Subjects: Get full text

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association by Alexander D. Woods, MD, Katelyn Kim, MD, Anna Axelson, MD

Subjects: Get full text

Editorial: Tertiary lymphoid structures (TLS) in the tumor immune microenvironment by Xinbo Gao, Xiangqin Zhao, Xuesong Li, Jin Zhang, Hui Zhao, Ying Ma

Subjects: Get full text

Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report by Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Eiji Takeuchi

Subjects: “…immune checkpoint inhibitors…”
Get full text

Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival by Jana Wellhausen, Louisa Röhl, Michael Berszin, Irene Krücken, Irene Krücken, Veit Zebralla, Veit Zebralla, Markus Pirlich, Markus Pirlich, Matthaeus Stoehr, Matthaeus Stoehr, Susanne Wiegand, Susanne Wiegand, Susanne Wiegand, Andreas Dietz, Andreas Dietz, Theresa Wald, Theresa Wald, Gunnar Wichmann, Gunnar Wichmann

Subjects: “…PD-1:PD-L1 immune-checkpoint inhibitor (ICI) pembrolizumab…”
Get full text

The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC by Yifan Wang, Yifan Wang, Jianying Zhou, Simin Peng, Simin Peng, Zhao Cui, Zhao Cui, Weiqi Wang, Weiqi Wang, Wenqin Zeng, Wenqin Zeng, Tingting Qiu, Zhentian Liu

Subjects: Get full text

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) by Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, Mariateresa Frascino, Mary Pitzalis, Laura Scalambra, Maria Sofia Semprini, Olga Maria Pittino, Chiara Cappello, Irene Siracusa, Ilaria Candida Chillico, Martina Di Noia, Cristian Turato, Silvia De Siervi, Francesco Lescai, Teresa Ciavattini, Giulia Lopatriello, Luca Bertoli, Hugo De Jonge, Luisa Iamele, Annalisa Altimari, Elisa Gruppioni, Andrea Ardizzoni, Marzia Rossato, Francesco Gelsomino, Pier-Luigi Lollini, Arianna Palladini

Subjects: Get full text

High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models by Hak Su Kim, Seung-hyun Kwon, Ok Kyung Choi, Taekyu Lim, Taekyu Lim

Subjects: Get full text

Case report: Multi-organ injuries induced by tislelizumab by Man Yuan, Man Yuan, Ning Han, Ning Han, Li Shu, Libo Yan, Libo Yan, Hong Tang, Hong Tang

Subjects: Get full text

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospectiv... by Gloria Juan-Carpena, Natividad Martínez Banaclocha, Juan Carlos Palazón Cabanes, Maria Niveiro-de Jaime, Isabel Betlloch Mas, Mar Blanes-Martínez

Subjects: Get full text

Catalysts of change: Immunotherapy's frontier in oral oncology by Shyamaladevi Babu, Madhan Krishnan

Subjects: Get full text